Skip to main content

Table 4 Occurrence and estimated cost of AIDS events

From: Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

AIDS event

Relative occurrence (%)

Number observed in UMCG (N)

Estimated Cost (€)

Candidiasis, oral or systemic

9.0

7

5,642

Herpes simplex

0.3

5

6,615

Kaposi sarcoma, cutaneous

3.8

1

1,972

Lymphoma

3.0

3

21,640

Mycobacterium avium complex

5.8

1

14,733

Pneumocystic pneumonia

13.0

7

8,214

Pneumonia

20.1

4

9,568

Tuberculosis

4.9

4

12,432

Toxoplasmic encephalitis

1.9

2

16,822

Wasting syndrome

22.8

1

4,072

Cryptococcal meningitis

1.2

1

11,354

Other

14.2

0

n.a.

Total

100

36

8,264

  1. Occurrence of AIDS events and estimated costs (Euro price level 2006) as observed in the UMCG. For 14.2% of all AIDS events no event data was available in the UMCG due to the relatively small number of patients. These types are Cervical cancer, Cytomegalovirus Retinitis, Cytomegalovirus Other, Coccidiosis, HIV-Dementia, Histoplasmosis, Kaposi sarcoma, visceral, Salmonella sepsis, Cryptosporidium, Progressive multifocal leucoencephalopathy
  2. UMCG: university medical center Groningen